Julian Adams, PhD
President of Research and Development
Infinity Pharmaceuticals Inc.
Julian Adams, Ph.D., is the president of research and development of Infinity Pharmaceuticals Inc. Dr. Adams received a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry. Prior to joining Infinity, Dr. Adams was the senior vice-president of drug discovery and development at Millennium Pharmaceuticals. In this capacity, he had global responsibility for multiple drug discovery programs, including the successful discovery and development of VELCADE®, a proteasome inhibitor for cancer therapy. Earlier in his career, Dr. Adams served in various positions at LeukoSite, ProScript Inc., and Boehringer Ingelheim, where he successfully discovered the drug Viramune® for HIV.
Dr. Adams is an inventor of over 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals, and is the editor of Proteasome Inhibition in Cancer Therapy. He has received many awards, including the 2001 Ribbon of Hope Award for VELCADE® from the International Myeloma Foundation and the AACR-Bruce F. Cain Memorial Award.